Hardman Res.: Funded to the end of Phase II trials

RNS Number : 8875Y

Evgen Pharma PLC

11 December 2017

 

Hardman Research: Funded to the end of Phase II trials

Increased funding to the end of Phase II trials: Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation. Evgen's proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time. SFX-01 is progressing in Phase II clinical trials for both subarachnoid haemorrhage and ER+ breast cancer, with readouts expected in or around the end of 2018. EVG has strengthened its balance sheet with a Placing to raise new funds of £2.3m gross.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/11.12.17-funded-to-the-end-of-phase-ii-trials.pdf

To contact us:    Hardman & Co 35 New Broad Street London EC2M 1NH

Analysts: Dr Martin Hall  [e-mail] Dr Dorothea Hill  [e-mail] Dr Gregoire Pave  [e-mail] Telephone: [phone] Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 

END

 

 

NRABIBDDXDGBGRI